Search Results - "Michot, M."

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report by Michot, J.-M., Albiges, L., Chaput, N., Saada, V., Pommeret, F., Griscelli, F., Balleyguier, C., Besse, B., Marabelle, A., Netzer, F., Merad, M., Robert, C., Barlesi, F., Gachot, B., Stoclin, A.

Get full text

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper by Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., Ederhy, S., Feuillet, S., François, H., Lazarovici, J., Le Pavec, J., De Martin, E., Mateus, C., Michot, J.-M., Samuel, D., Soria, J.-C., Robert, C., Eggermont, A., Marabelle, A.

“…Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma…”
Get full text

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies by Collins, M., Michot, J.M., Danlos, F.X., Mussini, C., Soularue, E., Mateus, C., Loirat, D., Buisson, A., Rosa, I., Lambotte, O., Laghouati, S., Chaput, N., Coutzac, C., Voisin, A.L., Soria, J.C., Marabelle, A., Champiat, S., Robert, C., Carbonnel, F.

“…Immune check-point blockade agents have shown clinical activity in cancer patients but are associated with immune-related adverse events that could limit their…”
Get full text

Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors by Michot, J.-M., Pruvost, R., Mateus, C., Champiat, S., Voisin, A -L, Marabelle, A., Lambotte, O.

Get full text

Quinolones in 2005: an update by Van Bambeke, F., Michot, J.-M., Van Eldere, J., Tulkens, P.M.

“…Quinolones are one of the largest classes of antimicrobial agents used worldwide. This review considers the quinolones that are available currently and used…”
Get full text

Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study by Quivoron, C, Michot, J-M, Danu, A, Lecourt, H, Saada, V, Saleh, K, Vergé, V, Cotteret, S, Bernard, O A, Ribrag, V

“…As a promising alternative to bone marrow aspiration (BMA), mutational profiling on blood-derived circulating cell-free tumor DNA (cfDNA) is a harmless and…”
Get full text

Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? by Michot, J.M., Lazarovici, J., Tieu, A., Champiat, S., Voisin, A.L., Ebbo, M., Godeau, B., Michel, M., Ribrag, V., Lambotte, O.

“…Immune checkpoint inhibitors (ICIs) are changing the treatments of many patients with cancer. These immunotherapies are generally better tolerated than…”
Get full text

Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency by Noël, N, Maigné, G, Tertian, G, Anguel, N, Monnet, X, Michot, J-M, Goujard, C, Lambotte, O

“…Hemolytic anemia with thrombocytopenia and schistocytosis is suggestive of thrombotic thrombocytopenic purpura (TTP). However, these features can occur in the…”
Get full text

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies by Pommeret, F., Colomba, J., Bigenwald, C., Laparra, A., Bockel, S., Bayle, A., Michot, J.-M., Hueso, T., Albiges, L., Tiberghien, P., Marot, S., Jary, A., Lacombe, K., Barlesi, F., Griscelli, F., Colomba, E.

Get full text

Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients by Valery, M., Saleh, K., Ecea, R., Michot, J. M., Ribrag, V., Fizazi, K., Hollebecque, A., Lecesne, A., Ponce, S., Loriot, Y., Champiat, S., Baldini, C., Sarkozy, C., Castilla-Llorente, C.

“…Background Cytokine release syndrome (CRS) is a common adverse event of CAR T cell or bispecific antibody (bsAb) therapy. Anti-IL6/IL6R drugs are used in the…”
Get full text

Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases by Gueiderikh, A, Ung, M, Lazarovici, J, Danu, A, Ghez, D, Saleh, K, Dragani, M, Noël, N, Bigenwald, C, Willekens, C, Ribrag, V, Michot, J-M, Martin, V

“…Follicular lymphoma (FL) is one of the most common lymphoma. Occasionally, FL is associated with tumoral epidural compression and management of these patients…”
Get full text

Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1 by Kfoury, M., Voisin, A.-L., Najean, M., Champiat, S., Laghouati, S., Michot, J.-M., Robert, C., Mateus, C., Albiges, L., Besse, B., Massard, C., Texier, M., Lambotte, O., Marabelle, A.

Get full text

Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes? by Leroy, L, Satar, T, Baldini, C, Martin-Romano, P, Hollebecque, A, Michot, J-M, Ribrag, V, Massard, C, Paoletti, X, Postel Vinay, S

Get full text

PB2102: PHASE 2 RANDOMIZED, OPEN‐LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL by Michot, J.‐M., Koh, Y., Lee, P., Jin, J., Clynes, R., Kye, S., Chiarella, M., Patel, K.

Get full text

Safety assessment of anti-PD(L)1 rechallenge after immune-related adverse events by Simonaggio, Michot, J.-M., Champiat, S., Vozy, A., Lapera, A., Marabelle, A., Le Pavec, J., Voisin, A.-L., Lallart, A., Cengizalp, G., Lambotte, O.

Get full text

Molecular alterations and matched treatment in older patients: Results from the MOSCATO 01 trial by Vuagnat, P., Baldini, C., Verlingue, L., Martin Romano, P., Varga, A., Hollebecque, A., Postel-Vinay, S., Gazzah, A., Bahleda, R., Marabelle, A., Ribrag, V., Champiat, S., Michot, J.-M., Soria, J.-C., Massard, C.

Get full text

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours by Herin, H., Aspeslagh, S., Castanon, E., Dyevre, V., Marabelle, A., Varga, A., Postel Vinay, S., Michot, J.M., Ribrag, V., Gazzah, A., Bahleda, R., Mir, O., Massard, C., Hollebecque, A., Soria, J.C., Baldini, C.

“…The development of immune checkpoint blocker development brings new hope in older patients (OPs) because of clinical efficacy and low toxicity. Clinical…”
Get full text

Incidence of immune related adverse events in patients 70 years old treated with anti-PD-(L)1 therapy by Baldini, C., Martin-Romano, P., Voisin, A.-L., Danlos, F.X., Champiat, S., Laghouati, S., Kfouri, M., Vincent, H., Nagera, C., Postel-Vinay, S., Varga, A., Ribrag, V., Besse, B., Hollebecque, A., Lambotte, O., Michot, J.-M., Soria, J.-C., Massard, C., Marabelle, A.

Get full text

Immune-related adverse events after immune checkpoints inhibitors in 2019: An update by Comont, T, Belliere, J, Sibaud, V, Alric, L, Meyer, N, Mazières, J, Caron, P, Acket, B, Michot, J-M, Beyne-Rauzy, O, Lambotte, O

“…Use of checkpoint inhibitors to treat cancer was one of the most important revolution these last years and an increasing number of new types of tumors is…”
Get full text

Precision medicine for patients with rare cancers: An effective strategy within the prospective MOSCATO trial by Abdelshafy, M., El Dakdouki, Y., Verlingue, L., Hollebecque, A., Lacroix, L., Postel-Vinay, S., Varga, A., Balheda, R., Michot, J.-M., Marabelle, A., Rouleau, E., Solary, E., de Baere, T., Angevin, E., Ribrag, V., Michiels, S., André, F., Scoazec, J.-Y., Soria, J.-C., Massard, C.

Get full text